Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades
CEO Takuro Wakabayashi describes the unmet need in stroke and how this asset found its way into to a partnership with RTW-based Corxel. Plus, further pipeline programs covering hypertension, kidney injury, and spinal cord injury.